drugset / Trial / NCT06910709

Single and Multiple Ascending Dose Study of AMG 378 in Healthy Participants

NCT06910709 ↗

Phase 1 Terminated 48 enrolled Amgen
RandomizedSequentialDouble-blindBasic science

Summary

The main objective of the study is to assess the safety and tolerability of AMG 378 as single or multiple doses in healthy participants.

Timeline

Start
2025-04-08
Primary completion
2025-12-02
Completion
2025-12-02

Outcome

Outcome not reported

Stopped (Business): “Business Decision”

Drugs

EvaluationDrugModalityDoseRoute
Subject AMG 378 Unknown — Oral

Indications

No indication recorded.